Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a One-Month TB prevention course beat the standard Three-Month regimen?

NCT ID NCT06191692

Prevention Sponsor: Freundeskreis Für Internationale Tuberkulosehilfe e.V Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 10, 2026 · Updated 1 time

Summary

Tuberculosis infection can progress to active, contagious TB disease, but preventive treatment often lasts three to nine months and many people do not finish it. This Phase 3 trial in Hanoi, Vietnam, compares a new one-month regimen of daily isoniazid and rifapentine with the standard three-month regimen of daily isoniazid and rifampicin. Researchers will enroll 350 adult household contacts of people with confirmed, drug-susceptible pulmonary TB who test positive for TB infection. The study measures how many participants in each group take at least 90% of their doses and tracks severe side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A one-month combination of isoniazid and rifapentine, compared with a three-month combination of isoniazid and rifampicin
What this could lead to
If the shorter regimen works as well, it could make TB preventive treatment easier to finish and more widely used, helping stop latent TB from becoming active disease.
What could go wrong
The trial may find the one-month regimen is not as well tolerated or as effective as the standard three-month course. Shorter treatment could also carry different side effects, and results in Vietnam may not apply everywhere.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Started

Nov 2024

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Household contacts of people with new, bacteriologically-confirmed, pulmonary, drug-susceptible TB who initiated treatment with residence in the intervention areas; * Positive QFT-Plus or TST results (TST induration of at least 5mm) * Agree to remain in contact and provide updated information as necessary, and have no current plans to relocate outside the designed area for the duration of the study; * Age ≥ 18 years; * Capable of providing signed informed consent; * Willing to participate in the study visits and procedures Exclusion Criteria: * Indeterminate results on QFT-Plus; * Clinical or radiographic suspicions or history of previous active TB; * Known hypersensitivity or contraindication to any components of the regimens; * Weight \<30kg; * Acute or chronic liver failure with elevated liver enzymes or evidence of liver dysfunction such as jaundice or a history of liver failure caused by isoniazid or rifampicin; History of liver cirrhosis at any time before study entry; * Infection with suspected or confirmed tuberculosis strains resistant to isoniazid or rifampicin; * Porphyria- Porphyrin metabolism disorder; * Polyneuropathy (self-reported/ confirmed); * Pregnant or planning to become pregnant within 120 days of enrollment; * Any other severe underlying condition that would, in the opinion of the investigator, compromise the patient's safety or outcome in the trial; * Participation in other clinical intervention trials or research protocols (participation in other studies that do not involve an intervention may be allowed, but this must be discussed and approved by the Chief Investigator).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Tuberculosis infection are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

latent tuberculosis infection tuberculosis active tuberculosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Tuberculosis infection

Contacts and locations

Locations

  • Ha Noi Lung Hospital

    Hà Nội, 10000, Vietnam

  • Vietnam National Lung Hospital

    Hanoi, Hanoi, 10000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.